CVC, a leading global private markets manager, has completed the previously announced acquisition of the Therakos business from Mallinckrodt plc (“Mallinckrodt”), a global specialty pharmaceutical company. The investment in Therakos from CVC Capital Partners Fund IX will provide the resources and expertise to further develop the business and its services which improve the lives of patients. Therakos is the leading company in Extracorporeal Photopheresis (ECP) delivery systems for autologous immunomodulatory therapy. With approvals for use in the U.S., Canada, Europe, Japan, Australia, Latin America and South Korea, the Therakos’ systems are the platform-of-choice among healthcare providers and patients to treat a range of immune-related diseases.
Read the full article: CVC Completes Acquisition of Therakos from Mallinckrodt //
Source: https://www.businesswire.com/news/home/20241202409570/en/CVC-Completes-Acquisition-of-Therakos-from-Mallinckrodt